Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Phase 1

Completed

• Conditions: Melanoma
• Interventions: Drug: TKI258

• Registration Number: NCT00303251
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects. The eligible subject population consists of subjects who have been diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-03-14
• Study First Submitted QC: 2006-03-15
• Study First Posted: 2006-03-16
• Study Start: 2006-04
• Primary Completion: 2009-09
• Status Verified: 2013-02
• Disposition First Submitted: 2013-02-09
• Disposition First Submitted QC: 2013-02-09
• Disposition First Posted: 2013-02-12
• Last Update Submitted: 2021-03-09
• Last Update Posted: 2021-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

• Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC or IV) that is refractory to standard therapy or for which no curative standard therapy exists.
• Measurable disease
• Must be eighteen years of age or older
• Must meet baseline laboratory requirements
• ECOG performance status 0 or 1
• Adults of reproductive potential must agree to use effective contraception or be sterile

Exclusion Criteria

• Concurrent therapy with any other investigational agent

• Uncontrolled central nervous system metastases

• Impaired cardiac function or clinically significant cardiac disease

• Received

  • chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks
  • biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks
  • an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting study drug or has not recovered from side effects of such therapy

• Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin is allowed.

• Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not recovered from side effects of such surgery.

• Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea, diarrhea, vomiting

• Pregnant or breast feeding women

• History of another primary malignancy that is currently clinically significant or currently requires active intervention.

• Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin.

• History of thromboembolic or cerebrovascular events within the last 12 months.

• History of rectal bleeding, bloody vomit, or spitting up blood within the last 3 months.

• Known diagnosis of HIV infection (HIV testing is not mandatory)

• Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort and quinidine is prohibited.

• Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study-drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, make the patient inappropriate for this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TKI258	TKI258	-

Primary Outcome Measures

Name	Time	Method
Dose Expansion: Determine the plasma and whole blood pharmacokinetics of orally administered TKI258	PK run-in days 1 & 2, cycle 1 days 1, 8, 15, 16, 28, cycle 2 day 15, cycle 2+ day 28
Dose Expansion: Determine the maximum tolerated dose based on dose limiting toxicity of TKI258	end of dose escalation
Dose Escalation: Assess tumor response according to RECIST as measured by response rate and lack of early progressive disease (<=2 months)	every 8 weeks

Secondary Outcome Measures

Name	Time	Method
Assess the effect of TKI258 on biomarkers in the blood	PK run day 1 & 2, cycle 1 day 2, 15, 28, cycle 2+ day 28, end of study
Assess the safety profile of TKI258 in this patient population	PK run in day 1 & 2, cycle 1 day 8, 15, 28, cycle 2+ day 15 & 28, end of study
Assess biomarker changes in tumor/nevi biopsies and archival tumor tissues where accessible, pre- and post-treatment	baseline, cycle 1 day 15, end of study
Assess changes in tumor glucose metabolism/cell viability between pre- and post-treatment using [18F]-FDG-PET	baseline, cycle 1 day 15, cycle 2 day 28
Assess anti-angiogenic effects of TKI258 using DCE-MRI pre- and post-treatment	baseline, cycle 1 day 2 and cycle 2 day 28

Trial Locations

Locations (3)

James Graham Brown Cancer Center; 🇺🇸 Louisville, Kentucky, United States

University of Pittsburgh Cancer Institute; 🇺🇸 Pittsburgh, Pennsylvania, United States

MD Anderson Cancer; 🇺🇸 Houston, Texas, United States